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A B S T R A C T
Background
Osteoarthritis (OA) is a common joint disorder. In the knee, injections of corticosteroids into the joint (intra-articular (IA)) may relieve
inflammation, and reduce pain and disability.
Objectives
To evaluate the efficacy and safety of IA corticosteroids in treatment of OA of the knee.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2003), MEDLINE, EMBASE, PREMEDLINE
(all to July 2003), and Current Contents (Sept 2000). Specialised journals, trial reference lists and review articles were handsearched.
Selection criteria
Randomised controlled trials of IA corticosteroids for patients with OA of the knee: single/double blind, placebo-based/comparative
studies, reporting at least one core OMERACT III outcome measure.
Data collection and analysis
Methodological quality of trials was assessed, and data were extracted in duplicate. Fixed effect and random effects models, giving
weighted mean differences (WMD), were used for continuous variables. Dichotomous outcomes were analysed by relative risk (RR).
Main results
Twenty-six trials (1721 participants) comparing IA corticosteroid against placebo, against IA hyaluronan/hylan (HA products), against
joint lavage, and against other IA corticosteroids, were included.
IA corticosteroid was more effective than IA placebo for pain reduction (WMD -17.79; 95% confidence interval (CI) -25.02 to -
10.55) and patient global assessment (the RR was 1.44 (95% CI 1.13 to 1.82)) at one week post injection with an NNT of 3 to 4 for
both, based on n=185 for pain on 100 mm visual analgoue scale (VAS) and n=158 for patient global assessment. Data on function
were sparse at one week post injection and neither statistically significant nor clinically important differences were detected.
There was evidence of pain reduction between two weeks (the RR was 1.81 (95% CI 1.09 to 3.00)) to three weeks (the RR was 3.11
(95% CI 1.61 to 6.01), but a lack of evidence for efficacy in functional improvement.
1Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
At four to 24 weeks post injection, there was lack of evidence of effect on pain and function (small studies showed benefits which did not
reach statistical or clinical importance, i.e. less than 20% risk difference). For patient global, there were three studies which consistently
showed lack of effect longer than one week post injection. However, all were fairly small sample sizes (less than 50 patients per group).
This was supported by another study which did not find statistically significant differences, at any time point, on a continuous measure
of patient global assessment (100 mm VAS).
In comparisons of corticosteroids and HA products, no statistically significant differences were in general detected at one to four weeks
post injection. Between five and 13 weeks post injection, HA products were more effective than corticosteroids for one or more of
the following variables: WOMAC OA Index, Lequesne Index, pain, range of motion (flexion), and number of responders. One study
showed a difference in function between 14 to 26 weeks, but no differences in efficacy were detected at 45 to 52 weeks. In general, the
onset of effect was similar with IA corticosteroids, but was less durable than with HA products.
Comparisons of IA corticosteroids showed triamcinolone hexacetonide was superior to betamethasone for number of patients reporting
pain reduction up to four weeks post injection (the RR was 2.00 (95% CI 1.10 to 3.63). Comparisons between IA corticosteroid and
joint lavage showed no differences in any of the efficacy or safety outcome measures.
Authors’ conclusions
The short-term benefit of IA corticosteroids in treatment of knee OA is well established, and few side effects have been reported. Longer
term benefits have not been confirmed based on the RevMan analysis. The response to HA products appears more durable. In this
review, some discrepancies were observed between the RevMan 4.1 analysis and the original publication. These are likely the result of
using secondary rather than primary data and the statistical methods available in RevMan 4.1. Future trials should have standardised
outcome measures and assessment times, run longer, investigate different patient subgroups, and clinical predictors of response (those
associated with inflammation and structural damage).
P L A I N L A N G U A G E S U M M A R Y
Osteoarthritis (OA) is the most common form of chronic arthritis worldwide. Intraarticular (IA) corticosteroid products provide
opportunity to treat OA in individual knee joints. To evaluate the efficacy, effectiveness and safety of IA corticosteroid products in
knee OA, we have conducted a systematic review using Cochrane methodology. The analyses support the contention that the IA
corticosteroid class of products is superior to placebo. The response is generally rapid, but may not be sustained in the longer term.
Hyaluronic acid (HA) products, while slower in onset of action, may have a more sustained duration of benefit. The types of patients
who may potentially benefit from IA corticosteroid versus HA therapy may differ. In general, sample size restrictions preclude any
definitive comment on the safety of the IA corticosteroid class of products; however, within the constraints of the trial designs employed,
no major safety issues were detected. Overall, the aforementioned analyses support the use of the IA corticosteroid class of products in
the treatment of OA knee.
B A C K G R O U N D
Osteoarthritis (OA) is the most frequent cause of rheumatic com-
plaints. OA of the knee is a leading cause of chronic disability
in the United States (Felson 2000; Felson 2000a). OA is a group
of distinct overlapping diseases, which may have different etiolo-
gies (causes), but have similar biologic, morphologic (form), and
clinical outcomes. The disease processes involve the entire joint,
including the articular cartilage (cartilage covering the bone sur-
faces in the joint), subchondral bone, ligaments, capsule, synovial
membrane (membrane covering the bone ends), and periarticular
muscles (muscles around the joint). Ultimately, the articular carti-
lage degenerates with fibrillation (the initial degenerative changes
in OA, marked by softening of the articular cartilage and develop-
ment of vertical clefts between groups of cartilage cells), exhibiting
fissures, ulceration, and a thinning of the joint surface (Brandt
1996).
Intra-articular (IA) corticosteroid therapy was first used by Hol-
lander in 1951 in Philadelphia to treat rheumatoid arthritis
(Hollander 1953). The first clinical trial in OA was performed
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in 1958 by Drs Miller, White and Norton in Glasgow (Miller
1958). Twenty years after the first use of IA corticosteroids, the
value of these injections was still questioned, with some authors
of the opinion that the injections could reduce pain in the short
term but were not helpful in treatment of the underlying arthritic
lesion (Helfet 1974). Even fifty years after the introduction of IA
corticosteroid therapy, concern was expressed regarding the mask-
ing of pain which allowed the patient to resume activity but pos-
sibly cause further destruction to the joint (Brandt 2001). In the
last few years, the efficacy of IA corticosteroids has been reviewed
in several publications (Ayral 2001; Creamer 1997; Gossec 2004;
Haraoui 2002; Kirwan 1997; Kirwan 2001; Towheed 1997).
In 1995, the American College of Rheumatology (ACR) pub-
lished guidelines for the treatment of OA of the knee (Hochberg
1995). These were updated in 2000 (ACR 2000) and state that,
for mild symptomatic OA, treatment may include non-pharmaco-
logic methods (patient education, physical and occupational ther-
apy and other therapies), and pharmacologic therapy (including
non-opioid oral and topical (i.e. applied to skin) analgesics). For
patients who are unresponsive to this regimen, the use of non-
steroidal anti-inflammatory drugs (NSAIDs) is considered appro-
priate. IA corticosteroid injection is recommended for patients
with knee OA, particularly when signs of local inflammation with
joint effusion (build-up of fluid within the joint) are present. Pa-
tients with severe symptoms of OA of the knee may require surgi-
cal intervention, e.g. osteotomy (operation intended to promote
healing of the joint) or total joint arthroplasty (replacement of the
joint with artificial components).
Although our review is restricted to OA of the knee joint, IA
corticosteroids have also been evaluated at other joints, includ-
ing: elbow, shoulder, wrist, hip, heel (McColl 2000), metacar-
pophalangeal and metatarsophalangeal joints, and lumbar facets
(Rozental 2000).
IA corticosteroids may provide short term pain relief. Long term
benefit has yet to be established. A systematic review of IA steroid
injections for kneeOAwith meta-analysis concluded that the ben-
eficial effect started one week after injection and could last for
three to four weeks (Godwin 2004). Evidence from another meta-
analysis supported short term (up to two weeks’) benefit in gen-
eral, with some longer term benefit lasting for 16 to 24 weeks
(Arroll 2004). In a journal supplement devoted to the role of the
general practitioner in managing OA and chronic musculoskele-
tal disease, these injections were recommended in combination
with other non-pharmacological and pharmacological therapies
(McColl 2001). McColl reported decreased pain and increased
function for up to six weeks with injections into joints that showed
evidence of joint effusion (McColl 2000). A European League
Against Rheumatism (EULAR) task force of the Standing Com-
mittee for International Clinical Studies Including Therapeutic
Trials recommended IA injection of long-acting steroid for acute
exacerbation (sudden worsening) of knee pain, especially if ac-
companied by effusion (Pendleton 2000). A clinical review of the
medicalmanagement ofOAbyWalker-Bone (Walker-Bone 2000)
concluded that “there was good evidence to support the judicious
use of IA corticosteroids in patients with knee OA, but because of
the potential for multiple IA injections to accelerate cartilage dam-
age”, they should not be monotherapy for patients with chronic,
stable OA. Two orthopaedic reviews (Noerdlinger 2001; Rozental
2000) have been completed. Noerdlinger recommended the judi-
cious use of injectable corticosteroids for inflamed tissue followed
by appropriate rehabilitation; this regimen provided pain relief
and sped-up the healing process. They stressed the importance
of proper technique. Rozental concluded that corticosteroid in-
jections provided significant pain relief, especially in combination
with non-steroidal anti-inflammatory drugs (NSAIDs), rest and
physical therapy. In an evidence-based review of the management
of OA in the primary care setting, Lane (Lane 1997) concluded
that IA corticosteroids could relieve pain and inflammation but
that the effect was of very short duration and so such therapy
should only be used infrequently. The potential effect of corticos-
teroids on disease progression is still hypothetical and is the subject
of clinical evaluation (Pelletier 2002). It is evident that contro-
versy still exists in the literature as to whether IA corticosteroids
are beneficial in the long term or whether the response is measured
only in days.
O B J E C T I V E S
To conduct a systematic review of randomised controlled trials
(RCTs) of IA corticosteroids for treatment of OA of the knee to
evaluate efficacy and safety over both short and long term.
R E S U L T S
Bias 2001 reported a four-week, parallel-group, non-blind RCT
performed at a single centre in Germany comparing one injection
of four mg dexamethasone palmitate (Lipotalon) (equivalent to
2.5 mg dexamethasone) to one injection of 12 mg dexamethasone
palmitate (equivalent to 7.5 mg dexamethasone) in 24 patients
with activated inflammatory OA of the knee. The objective of
this trial was primarily to investigate the pharmacokinetics of this
formulation of the corticosteroid. Consequently, efficacy was not
evaluated with a formal statistical analysis; rather a descriptive
analysiswas reported.The lowest disease activity index score (based
on investigator rating of pain, temperature, effusion, and swelling)
was recorded 16 days post injection in both groups. The largest
reduction in pain was detected after an average of four days. No
adverse eventswere recorded for any of the patients for the duration
of the trial.
Caborn et al. (Caborn 2004) reported a 26-week, parallel-group,
single-blind RCT performed at 14 centres in the United States
3Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
comparing three weekly injections of Hylan G-F 20 to one IA
injection of triamcinolone hexacetonide (Aristospan) in 218 pa-
tients with OA of the knee. The onset of action was faster in the
triamcinolone hexacetonide group. However, treatment with Hy-
lan G-F 20 resulted in a longer duration of effect. Both treatments
were well tolerated with 10% of patients in each group reporting
an adverse event that resulted in withdrawal from the trial.
The Caborn et al. trial (Caborn 2004) was single-blind and de-
tails regarding the method of randomisation were not published.
The triamcinolone hexacetonide group received only one injec-
tion compared to the three injections administered to the Hy-
lan G-F 20 group. Analgesic and NSAID usage were monitored
throughout this trial. Patients with effusion of greater than10 ml
were excluded. Almost 30% of each treatment group had severe
radiological ratings while approximately 60% in each group had
moderate ratings.
Cederlof and Jonson (Cederlof 1966) reported an eight-week, par-
allel-group, double-blindRCTcomparing IA prednisolone acetate
(50 mg) to saline in 44 patients with OA of the knee. No differ-
ences were found between the two groups in the efficacy outcomes.
No information on adverse events was reported in the publication.
Dieppe et al. (Dieppe 1980a, Dieppe 1980b) reported two trials
in one publication. The first (Dieppe 1980a) was a six-week, par-
allel-group, single-blind RCT comparing IA triamcinolone hex-
acetonide (20 mg) to saline in 12 patients with bilateral OA of the
knee. Maximum benefit in pain score was reported in the IA cor-
ticosteroid group one week post injection. No information on ad-
verse events was reported. The second (Dieppe 1980b) was a one-
week, cross-over, single-blind RCT comparing IA triamcinolone
hexacetonide (20 mg) to saline in 16 patients with OAof the knee.
The IA corticosteroid group was significantly (P value <0.05) bet-
ter than saline for reducing pain and tenderness. No information
on adverse events was reported.
Friedman and Moore (Friedman 1980) reported an eight-week,
parallel-group, double-blind RCT comparing IA triamcinolone
hexacetonide (20 mg) with placebo (suspending vehicle) in 34
patients with OA of the knee. Significantly less pain was reported
by the IA corticosteroid group at one week post injection. Post
injectionflares (either increased pain, heat or swelling in the first 24
h after injection) occurred with similar frequency in both groups.
Frizziero and Pasquali Ronchetti (Frizziero 2002) reported a six-
month, parallel group, single-blind RCT performed at a single
centre in Italy comparing five weekly injections ofHyalgan to three
weekly injections of methylprednisolone acetate in 99 patients
with primary or secondary OA of the knee. The authors found an
initial statistically significant difference in favour of methylpred-
nisolone acetate at day 35 but not at day 180. The clinical effect
with Hyalgan appeared more gradually but lasted longer than that
of methylprednisolone acetate. Arthroscopic evaluations showed
thatHyalgan was superior tomethylprednisolone acetate in reduc-
ing the extent and grade of cartilage damage. No adverse events
were reported in the Hyalgan group compared to two patients in
themethylprednisolone acetate group, one resulting in withdrawal
from the trial.
This RCT was one of the trials which examined the structural
effects of Hyalgan using both arthroscopic and microarthroscopic
examinations.
Gaffney et al. (Gaffney 1995) reported a six-week, parallel-group,
double-blind RCT comparing IA triamcinolone hexacetonide (20
mg) with saline in 84 patients with OA of the knee. One of the
purposes of this trial was to examine factors that could influence
the clinical response. Pain relief was significantly greater (P value
<0.01) in the IA corticosteroid group at one week post injection.
This greater improvement in pain was associated with clinical ev-
idence of an effusion (P value <0.05) and aspiration of synovial
fluid at time of injection (P value <0.01). Two patients in the saline
group withdrew at week one due to treatment inefficacy.
Jones et al. (Jones 1995) reported a 29-week, parallel-group, dou-
ble-blind RCT comparing IA hyaluronic acid to IA triamcinolone
hexacetonide (20 mg) in 63 patients with bilateral knee OA with
effusion. Active treatment was always given to the worse knee.
The contralateral knee received placebo injections of saline. This
review compared IA triamcinolone hexacetonide in active knees
to saline in the placebo knees in the 31 patients randomised to
IA triamcinolone hexacetonide. No difference was found between
the two groups in pain on a self-selected activity, which was the
primary outcome measure. Seventy-four percent of the patients
in the IA triamcinolone hexacetonide group withdrew during the
trial, leaving 8 patients available for assessment at Week 29; 13/23
(57%) patients withdrew because of worsening of knee symptoms
and slow improvement.
Jones and Doherty (Jones 1996) reported an eight-week, cross-
over, double-blind RCT comparing IA methyl prednisolone ac-
etate (40 mg) with saline in 60 patients with OA of the knee.
Pain was significantly (P value <0.0001) reduced at three weeks
post injection in favour of IA corticosteroid compared to saline.
Similarly to the Gaffney trial (1995), the authors tried to identify
clinical predictors of response. No clinical predictors of response
were identified. Twelve patients withdrew prematurely from the
trial: three due toworsening symptoms (two after IA corticosteroid
and one after saline), one patient’s symptoms resolved, and eight
withdrew for unrelated reasons.
Leardini et al. (Leardini 1987) reported a one-year, single-blind,
parallel groupRCTperformed at a single centre in Italy comparing
three weekly injections of Hyalgan to three weekly injections of
methylprednisolone acetate (MPA) in 36 patients with OA of the
knee. No statistically significant differences were found between
the two groups in the clinical assessments. Local reactions were
reported in three patients in the MPA group compared to four
patients in the Hyalgan group.
4Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
This trial reported results on 40 joints of 36 patients (4 with
bilateral disease).
Leardini et al. (Leardini 1991) reported a 60-day, open-label, par-
allel-group RCT performed at a single centre in Italy comparing
three weekly injections of Hyalgan to three weekly injections of
6-methylprednisolone acetate (6-MPA) in 40 patients with OA of
the knee. All patients were kept ’at rest’ for two days after injec-
tion. Assessments, completed one week after the end of treatment,
showed that Hyalgan was comparable to 6-MPA. In the longer
term, significant differences were found in favour of Hyalgan for
the pain outcomes. All patients completed the treatment schedule.
No local or systemic reactions were reported.
Leopold et al. (Leopold 2003) reported a six-month, single-blind,
parallel-group, RCT performed at a single centre in the United
States comparing three weekly injections of Hylan G-F 20 to one
injection of betamethasone sodium phosphate-betamethasone ac-
etate (Celestone Soluspan), which could be repeated during the
study, in 100 patients with OA of the knee. No differences in pain
or function were found between the two groups at the six months
follow-up. Neither treatment worked well in females. One patient
in the Hylan G-F 20 group withdrew because of an acute local
reaction. One-fifth of the study population withdrew because of
a lack of treatment efficacy. Only safety data have been extracted
from this trial. Since the outcome variables had results that were
not normally distributed, nonparametric statistical methods were
used to analyze the data (e.g. change in median outcomes scores).
The Leopold et al. (Leopold 2003) trial was an independent trial
not funded by the manufacturer of the hyaluronate-based prod-
uct under study. The injection procedure was standardised by:
1) patient was in the supine position, 2) the injection was made
superolaterally into the suprapatellar notch, and 3) patients were
encouraged to refrain from strenuous activity for a day. However,
effusions were aspirated in the HA group whereas they were not
in the corticosteroid group. In addition, patients in the corticos-
teroid group were permitted to have one more injection any time
during the study. The authors chose not to use the Ahlback radio-
graphic grading system, ’because three of the four stages include
knees with a completely obliterated joint space’. This was the only
trial to find a gender difference in treatment response.
Miller et al. (Miller 1958) reported a 24 week, parallel-group, dou-
ble-blind RCT in 202 patients with OA of the knee. Five IA forms
of injection were compared: lactic acid plus novocaine solution,
novocaine solution, hydrocortisone (25 mg), saline, and mock in-
jection.This review comparedhydrocortisonewith saline. Twenty-
one patients withdrew from the trial prematurely: five patients ex-
perienced relief after one injection, two patients had an acute reac-
tion after injection, three patients were dissatisfied with treatment,
two patients emigrated, and nine cases were lost to follow up. At
six weeks post injection, there was no difference between any of
the five groups based on percentage of patients improved. At the
second assessment , six months after the first review, a further 14
patients were lost to follow up: six died of intercurrent disease and
eight did not wish to continue. In the remaining 167 patients,
there was no significant difference between the injections.
Pietrogrande et al. (Pietrogrande 1991) reported a 60-day, open-
label, parallel-group RCT performed at three centres in Italy com-
paring five weekly injections of Hyalgan to three weekly injections
of 6-methylprednisolone acetate in 90 patients with OA of the
knee. Although both treatments reduced the disease symptoms, 6-
MPA had a more rapid action but did not last as long as Hyalgan.
At the final assessment, significant differences were found between
the treatments for most outcome measures. One patient in the
Hyalgan group had a local reaction which resolved spontaneously
but was withdrawn due to lack of efficacy. No systemic adverse
reactions were reported in either group.
Popov et al. (Popov 1989) reported a 20 day, parallel-group, dou-
ble-blind RCT in 48 patients with OA of the knee and associated
signs of limited synovitis in one knee. Five IA forms of injection
were compared: triamcinolone acetonide (40 mg), hydrocortisone
acetate (50 mg), aprotinin (50,000 units), polyvinylpyrrolidone
andphysiologic solution.Results indicated that triamcinolone ace-
tonide and hydrocortisone acetate were significantly better than
physiologic solution. Aprotinin and polyvinylpyrrolidone were no
more effective than physiologic solution. No difference in efficacy
between triamcinolone acetonide and hydrocortisone acetate was
detected. Only one patient developed pain, swelling and itch after
the second and third injections of aprotinin.
Pyne et al. (Pyne 2004) reported an eight-week, parallel-group,
double-blindRCTcomparing triamcinolone hexacetonide (THA)
(20 mg) with methylprednisolone acetate (MPA) (40 mg) in 57
patients with OA of the knee. Both steroids provided short-term
effectiveness. THA was more effective than MPA at week three in
pain reduction, but lost its effect by week eight. MPA had a slower
onset of action with benefit lasting to eight weeks. There were no
dropouts in this trial. There were no reports of skin or soft tissue
necrosis along the needle track.
Ravaud et al. (Ravaud 1999) reported a 24-week, placebo-con-
trolled, 2x2 factorial design RCT in 98 patients with OA of the
knee. Four groups were compared: 1) IA placebo (saline), 2) IA
corticosteroid (Cortivazol 3.75mg), 3) joint lavage and IA placebo
(saline), and 4) joint lavage and IA corticosteroid (Cortivazol).
The Cortivazol group had significantly (P value 0.02) improved
pain VAS scores at week 4. The joint lavage group had significantly
(P value 0.02) improved pain VAS scores at week 24. The com-
bination therapy of joint lavage and IA corticosteroid produced
an additive effect. The authors suggested that this combination
“might be of faster and stronger efficacy” than the monotherapy
regimens. Twenty-three patients withdrew prematurely from the
trial; 19 due to inefficacy and four lost to follow up. The frequency
of local discomfort was significantly (P value 0.012) higher with
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joint lavage compared to IA injection.
Raynauld et al. (Raynauld 2003) reported a two-year, placebo-con-
trolled, double-blind RCT comparing triamcinolone acetonide 40
mg (Kenalog) with saline (one cc) in 68 patients with OA of the
knee. The authors found no difference between the two groups in
joint space width after one and two years of treatment. At the end
of the first year, the corticosteroid group had a significantly greater
change in range of motion and a slightly greater improvement in
pain compared to the saline group. Knee pain and stiffness were
significantly improved over the two years in the steroid group but
not in the saline group. The trial supported the long-term safety
of IA steroid injections.
Smith et al. (Smith 2003) reported a 24-week, placebo-controlled,
double-blind RCT comparing arthroscopic lavage plus methyl-
prednisolone acetate (120 mg) with arthroscopic lavage plus nor-
mal saline in 77 patients with OA of the knee. There were no sig-
nificant differences between the two groups for pain, stiffness or
WOMAC or Lequesne assessments at any assessment. There was a
significant difference at four weeks in the OARSI response criteria
in favour of theMPA group (58%) compared to the placebo group
(33%). There were no side effects from the IA injections. Three
patients required further sutures of arthroscopy portals because of
leakage of synovial fluid.
Tascioglu and Oner (Tascioglu 2003) reported a six-month, paral-
lel-group, open-label RCT performed at a single centre in Turkey
comparing three weekly injections of Orthovisc to three weekly
injections of 6-methylprednisolone acetate (6-MPA) in 69 female
patients with OA of the knee. In this trial, paracetamol (to a maxi-
mum of three g daily) was permitted but with restriction 48 hours
prior to an assessment. The percentage of patients with uni/bi-
lateral disease was not reported. A significant improvement was
reported in both groups at week four in pain and Lequesne Index
outcome measures. At three months, a significant improvement
in pain and Lequesne Index was reported in favour of Orthovisc
compared to 6-MPA. By six months, there was no difference be-
tween the two groups. No serious systemic adverse events were re-
ported that could be related to the treatment. Similar percentages
of patients reported knee pain after injection (Orthovisc 21%, 6-
MPA 18%). There was no significant between group difference
with respect to adverse events.
Tekeoglu et al. (Tekeoglu 1998) reported a 15-week, parallel-
group, open label RCT performed in Turkey comparing three
weekly injections of Orthovisc to three weekly injections of be-
tamethasone in 40 female patients with OA of the knee. In the
short-term (week three), betamethasone was more effective than
Orthovisc. In the long-term (week 15), Orthovisc was more ef-
fective than betamethasone. No local or systemic reactions were
reported.
The Tekeoglu et al. (Tekeoglu 1998) trial allowed patients to take
paracetamol as well. Again, the percentage of patients with uni
or bilateral disease was not reported. In this RCT, patients were
advised to rest for one day after injection ’to avoid overcharging
the injected joint’.
Thorpe (Thorpe 1985) reported a 20-week, parallel-group, dou-
ble-blind RCT comparing triamcinolone acetonide (10 mg) with
methylprednisolone acetate (40 mg) in 44 patients with OA of
the knee. No significant differences between the two groups were
reported. This study provided evidence that a smaller quantity of
IA triamcinolone acetonide was just as effective as a larger dose of
IA methylprednisolone acetate. Both IA corticosteroids were well
tolerated with no local or systemic adverse events being reported
in either group.
Valtonen (Valtonen 1981) reported a 24-week, parallel-group, sin-
gle-blind RCT comparing triamcinolone hexacetonide (20 mg)
with a combination of betamethasone acetate and betamethasone
disodium phosphate (BM) (6 mg) in 42 patients with OA of the
knee with inflammation. Although both groups had significant
improvement in pain one week post injection, triamcinolone hex-
acetonide was significantly superior (P value <0.005) compared
to BM. This study evaluated duration of effect ’as the time that
elapsed between one IA injection of triamcinolone hexacetonide
or BM and the patient’s request of further therapy or reinjection’.
The duration of effect was significantly longer with triamcinolone
hexacetonide. No patients withdrew prematurely from the trial.
However, local pain after injection was reported by four of 21
patients in the triamcinolone hexacetonide group and one of 21
patients in the BM group.
Wright et al. (Wright 1960) reported a 40-week, cross-over, dou-
ble-blind, three-arm RCT of hydrocortisone acetate (25 mg), hy-
drocortisone tertiary-butylacetate (25 mg) and suspending vehicle
in 25 patients with OAof the knee. No significant differences were
found between the two IA corticosteroids. Although injection of
both IA corticosteroids resulted in improvement in pain compared
to placebo at two weeks post injection, this improvement was only
significant (P value 0.02) in the hydrocortisone tertiary-butylac-
etate group. Increased pain and stiffness lasting three days was re-
ported in two knees treated with IA corticosteroid.
Young et al. (Young 2001) reported a four-week, placebo-con-
trolled, double-blind RCT performed in Australia comparing
arthroscopy followed by methylprednisolone acetate (120 mg)
with arthroscopy followed by IA normal saline in 40 patients with
OA of the knee. The objective of this trial was to investigate the
effects of IA corticosteroid on macrophage infiltration, the expres-
sion of the chemokines MCP-1 and MIP-1alpha, and the expres-
sion of MMPs 1 and 3 and their inhibitors, TIMPs 1 and 2, in
OA synovial tissue. The authors found a statistically significant
reduction in the WOMAC score within the MPA group but no
decrease in the placebo group. No safety data were reported in the
publication.
Corticosteroid versus placebo: pain
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Eight of the thirteen trials comparing corticosteroid with placebo
reported some measure of pain.
Friedman (Friedman 1980) detected no statistically significant dif-
ference in the number of patients reporting pain reduction at ei-
ther one week post injection (88% triamcinolone hexacetonide
versus 71% vehicle), the relative risk (RR) was 1.25 (95% confi-
dence interval (CI) 0.88 to 1.78; P value 0.2); or eight weeks post
injection (65% triamcinolone hexacetonide versus 65% vehicle),
the RR was 1.00 (95% CI 0.61 to 1.64; P value 1).
Using a numerical pain rating scale 0 to 10 and the Mann-Whit-
ney U test, the Friedman publication reported a statistically signif-
icant difference (P value < 0.008) in favour of the triamcinolone
hexacetonide group at one week post injection (Friedman 1980).
Since no measure of dispersion (i.e. standard deviation) was re-
ported, this outcome was not included in the RevMan analysis.
In Wright’s trial (Wright 1960), no statistically significant differ-
ence was detected in the number of knees reported as improved
with respect to pain between hydrocortisone acetate (50%) and
vehicle (36%) at two weeks post injection, the RR was 1.38 (95%
CI 0.79 to 2.39; P value 0.3).However, in the same trial there was a
statistically significant difference in the number of improved knees
in the hydrocortisone tertiary-butylacetate group (66%) compared
to the vehicle group (36%); the RR was 1.81 (95% CI 1.09 to
3.00; P value 0.02). Therefore, the number needed to treat (NNT)
with hydrocortisone tertiary-butylacetate versus vehicle to achieve
an improvement in pain two weeks post injection was three.
Ravaud (Ravaud 1999) defined responders in terms of at least a
30% decrease in pain VAS from baseline. A statistically significant
difference was detected in the number of responders (64% Corti-
vazol versus 25% saline) at one week post injection; the RR was
2.56 (95% CI 1.26 to 5.18; P value 0.009). This is equivalent to
a 39% risk difference, and an NNT of 2.6. No statistically sig-
nificant difference was detected in the number of responders at
four weeks (56% Cortivazol versus 29% saline), the RR was 1.96
(95% CI 0.99 to 3.87; P value 0.05); twelve weeks (52% Cortiva-
zol versus 29% saline), the RR was 1.82 (95% CI 0.91 to 3.65; P
value 0.09); or twenty-four weeks post injection (48% Cortivazol
versus 22% saline), the RR was 2.24 (95% CI 0.99 to 5.08; P
value 0.05).
Jones (Jones 1996) defined responders in terms of a 15% reduc-
tion in pain. A statistically significant difference was detected in
the number of responders (47% methylprednisolone versus 15%
saline) at three weeks post injection; the RR was 3.11 (95% CI
1.61 to 6.01; P value 0.0007). This equates to a 32% risk differ-
ence. The NNT with methylprednisolone versus saline to achieve
an improvement at three weeks post injection in the number of
responders was three.
Pain, assessed on a 0 to100mmVAS, showed a significantly greater
improvementwith IA corticosteroid than placebo at oneweek post
injection (WMD (FE) -17.79; 95%CI -25.02 to -10.55; P value <
0.00001) (Dieppe 1980a; Dieppe 1980b; Gaffney 1995; Ravaud
1999). At two weeks post injection (Dieppe 1980a) RR was 0
(95% CI -20.00 to 20.00; P value 1); four weeks post injection
(Dieppe 1980a; Ravaud 1999) RR was -7.96 (95% CI -20.01 to
4.09; P value 0.2); and six weeks post injection (Dieppe 1980a;
Gaffney 1995) RRwas -5.58 (95%CI -15.58 to 4.43; P value 0.3);
no statistically significant differences were detected. A statistically
significant difference in favour of Cortivazol was detected at 12
weeks post injection in the Ravaud (Ravaud 1999) trial (WMD
(FE) -14.20; 95% CI -27.44 to -0.96; P value 0.04). Cortivazol
was 31% more effective than saline. No statistically significant
difference was detected at 24 weeks post injection, RR was -7.30
(95% CI -22.61 to 8.01; P value 0.3) (Ravaud 1999).
There was a statistically significant difference in favour of tri-
amcinolone acetonide compared to saline in the Raynauld trial
(Raynauld 2003) for WOMAC pain (0 to 100 mm VAS) at one
year post injection (WMD -13.80; 95% CI -23.56 to -4.04; P
value 0.006). Triamcinolone acetonide was 13% more effective
than saline. No difference was detected at two years post injec-
tion (WMD -5.20; 95% CI -15.03 to 4.63; P value 0.3). The
RevMan analysis differed from the Raynauld publication analysis
in which no difference was found between the treatment groups
for WOMAC pain at one year. The publication used a 2-sample
t-test at one-year resulting in a P value of 0.22.
There was no statistically significant difference in pain at night (0
to 100 mm VAS) at one year post injection (WMD -5.10; 95%
CI -14.66 to 4.46; P value 0.3); or at two years post injection
(WMD 1.20; 95% CI -9.29 to 11.69; P value 0.8) (Raynauld
2003). The RevMan analysis differed from the original analysis
in the Raynauld publication for pain at night at two years. The
original analysis, which was based on area under the curve of the
normalized values for night pain, reported a statistically significant
difference (P value 0.0047) in favour of triamcinolone acetonide.
However, using analysis of variance for repeatedmeasurements, no
statistically significant difference was found at two years (P value
0.74).
Corticosteroid versus placebo: function
Three of the 13 trials comparing corticosteroid with placebo re-
ported a measure of physical function that could be extracted.
No statistically significant differences were detected in the
Lequesne Index (scored 0 to 24) at oneweek post injection (WMD
-2.20; 95%CI -4.87 to 0.47; P value 0.11), at four weeks (WMD -
2.30; 95%CI -4.67 to 0.07; P value 0.06), 12weeks (WMD-1.00;
95% CI -3.32 to 1.32; P value 0.4), or 24 weeks (WMD -1.20;
95% CI -3.58 to 1.18; P value 0.3) in the Ravaud trial (Ravaud
1999). No statistically significant differences were detected in the
modified Health Assessment Questionnaire (scored 0 to 9) at one
week post injection (WMD -0.10; 95% CI -0.96 to 0.76; P value
0.8) or at six weeks (WMD 0.30; 95% CI -0.62 to 1.22; P value
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0.5) (Gaffney 1995). No statistically significant differences were
detected in walking distance (measured in metres) at one week
post injection (WMD 2.40; 95% CI -4.36 to 9.16; P value 0.5),
or at six weeks (WMD -0.80; 95% CI -7.20 to 5.60; P value 0.8)
(Gaffney 1995).
In the Raynauld trial (Raynauld 2003), there was a statistically
significant difference between triamcinolone acetonide and saline
at two years post injection for range of motion (ROM) mea-
sured in degrees (WMD 10.40; 95% CI 8.45 to 12.35; P value
0.00001), but not at one year (WMD -1.30; 95% CI -3.01 to
0.41; P value 0.14). Triamcinolone acetonide was 10% more ef-
fective than saline in improving range of motion at two years. The
RevMan analysis differed from the original Raynauld analysis in
which no difference had been found between the groups for range
of motion at two years (P value 0.16, by analysis of variance for re-
peated measurements). Results showed no statistically significant
differences for WOMAC Physical Function (0 to 100 mm VAS)
at one year post injection (WMD -6.00; 95% CI -16.01 to 4.01;
P value 0.2), or at two years (WMD -4.20; 95% CI -20.30 to
11.90; P value 0.6); or for 50-foot walking time at one year post
injection (WMD -0.20; 95% CI -1.67 to 1.27; P value 0.8), or at
two years (WMD -0.70; 95% CI -2.17 to 0.77; P value 0.4).
Corticosteroid versus placebo: global assessment
Nine out of 13 trials comparing corticosteroid with placebo re-
ported a measure of patient global assessment.
The Ravaud and Raynauld trials (Ravaud 1999; Raynauld 2003)
used a 0 to 100 mm VAS for assessing patient global assessment.
No statistically significant differences were detected at any of the
follow-up assessments: at one week post injection(WMD -15.50;
95% CI -32.32 to 1.32; P value 0.07), four weeks (WMD -12.90;
95% CI -29.51 to 3.71; P value 0.13); 12 weeks (WMD -9.20;
95% CI -24.18 to 5.78; P value 0.2), 24 weeks (WMD -3.70;
95% CI -20.47 to 13.07; P value 0.7), 52 weeks (WMD -0.40;
95% CI -9.22 to 8.42; P value 0.9), or 104 weeks post injection
(WMD -1.10; 95% CI -12.00 to 9.80; P value 0.8).
Treatment preference was assessed in three trials (Dieppe 1980a;
Dieppe 1980b; Jones 1996). In all three trials, IA corticosteroid
was preferred over placebo, 83%versus 17%(Dieppe 1980a), 83%
versus 46% (Dieppe 1980b), and 51% versus 24% (Jones 1996);
RR (FE) was 2.22 (95% CI 1.57 to 3.15; P value 0.00001). This
is equivalent to a risk difference of 35%, and a NNT of three.
In terms of number of patients showing improvement, a statisti-
cally significant difference was detected in favour of IA corticos-
teroid compared to placebo at one week post injection (Cederlof
1966; Gaffney 1995; Popov 1989); RR (FE) was 1.44 (95% CI
1.13 to 1.82; P value 0.003). This is equivalent to a risk difference
of 23%, and a NNT of four. There were no significant differences
detected, and no evidence of effect, from three to 24 weeks post
injection. (At three weeks post injection RR was 0.91 (95% CI
0.67 to 1.24; P value 0.6) (Cederlof 1966), at six weeks RR was
1.06 (95% CI 0.86 to 1.31; P value 0.6) (Gaffney 1995; Miller
1958), at eight weeks RR was 0.86 (95% CI 0.60 to 1.23; P value
0.4) (Cederlof 1966), and at 24 weeks RR was 0.94 (95% CI 0.81
to 1.09; P value 0.4) (Miller 1958)).
Corticosteroid versus placebo: other outcome measures
There were no statistically significant differences between triamci-
nolone acetonide and saline for WOMAC stiffness (0 to 100 mm
VAS) in the Raynauld trial (Raynauld 2003) at one year (WMD
-6.70; 95% CI -19.24 to 5.84; P value 0.3), or at two years post
injection (WMD -8.60; 95% CI -20.78 to 3.58; P value 0.17).
The RevMan analysis differed from the original Raynauld analysis
where a statistically significant difference (P value 0.0511) was re-
ported in favour of triamcinolone acetonide inWOMAC stiffness
using area under the curve of the normalized values for knee stiff-
ness. However, when analysis of variance for repeated measure-
ments was used, no statistically significant difference was detected
at two years (P value 0.86).
There were no statistically significant differences between triamci-
nolone acetonide and saline forWOMACtotal score (0 to 100mm
VAS) in the Raynauld trial (Raynauld 2003) at one year (WMD
-7.80; 95% CI -17.19 to 1.59; P value 0.10), or at two years post
injection (WMD -4.60; 95% CI -16.98 to 7.78; P value 0.5).
There were no statistically significant differences between triam-
cinolone acetonide and saline for joint space width (mm) in the
Raynaud trial (Raynauld 2003) at one year (WMD 0.14; 95% CI
-2.90 to 3.18; P value 0.9), or at two years post injection (WMD
0.16; 95% CI -2.23 to 2.55; P value 0.9).
Corticosteroid versus placebo: safety
No statistically significant differences were detected in the total
number of withdrawals overall, RR was 0.60 (95% CI 0.25 to
1.45; P value 0.3) or in the number of withdrawals due to lack of
efficacy, RR was 0.61 (95% CI 0.23 to 1.65; P value 0.3) (Ravaud
1999; Raynauld 2003).
No statistically significant differences were detected in the number
of patients reporting post injection flare, RR was 0.80 (95% CI
0.26 to 2.48; P value 0.7) (Friedman 1980), or in the number of
patients reporting local discomfort, RR was 0.45 (95% CI 0.10
to 2.11; P value 0.3) (Ravaud 1999).
Corticosteroid versus joint lavage plus intra-articular placebo:
efficacy
Two trials compared IA corticosteroid and arthroscopic joint
lavage (Ravaud 1999; Smith 2003).
No statistically significant differences were detected in the Ravaud
trial (Ravaud 1999) for the following four outcome measures:
number of responders defined as at least a 30% reduction in pain
VAS from baseline; pain on a 100 mm VAS; the Lequesne Index;
or in the global assessment scored on a 100 mm VAS.
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The statistical values supporting these results were:
Number of responders: at one week post injection the RR was
1.34 (95% CI 0.79 to 2.30; P value 0.3), at four weeks the RR
was 1.18 (95% CI 0.67 to 2.07; P value 0.6), at 12 weeks the RR
was 1.09 (95% CI 0.61 to 1.96; P value 0.8), at 24 weeks the RR
was 1.01 (95% CI 0.55 to 1.85; P value 1).
Pain on a 100mmVAS: at one week post injection (WMD-12.00;
95%CI -26.66 to 2.66; P value 0.11), at four weeks (WMD -5.90;
95% CI -21.83 to 10.03; P value 0.5), at 12 weeks (WMD 4.50;
95% CI -11.34 to 20.34; P value 0.6), and at 24 weeks (WMD
3.10; 95% CI -13.48 to 19.68; P value 0.7).
Lequesne Index (0 to 24): at one week post injection (WMD -
0.90; 95% CI -3.45 to 1.65; P value 0.5), at four weeks (WMD
-0.30; 95% CI -2.89 to 2.29; P value 0.8), at 12 weeks (WMD
1.00; 95%CI -1.51 to 3.51; P value 0.4), and at 24 weeks (WMD
0.60; 95% CI -2.11 to 3.31; P value 0.7).
Patient global assessment (0 to 100 mm VAS): at one week post
injection (WMD -9.90; 95% CI -27.27 to 7.47; P value 0.3), at
four weeks (WMD -1.10; 95% CI -18.85 to 16.65; P value 0.9),
at 12 weeks (WMD 6.90; 95% CI -10.76 to 24.56; P value 0.4),
and at 24 weeks post injection (WMD 8.20; 95% CI -10.22 to
26.62; P value 0.4).
In the Smith trial (Smith 2003), there was a statistically significant
difference in the presence of effusion in favour of arthroscopy
with methylprednisolone acetate compared to arthroscopy with
saline at two weeks post injection only. There were no statistically
significant differences detected at other time points, or for the
outcomes of pain on movement, or the proportion of OARSI
criteria responders at any follow-up point.
The statistical values supporting these results were as follows:
In the presence of effusion: at two weeks post injection RR was
0.19 (95% CI 0.04 to 0.83; P value 0.03; NNT = 5). At the
four subsequent follow-up assessments there were no statistically
significant differences: at four weeks RR was 0.47 (95% CI 0.20
to 1.14; P value 0.10), at eight weeks RR was 0.47 (95% CI 0.20
to 1.14; P value 0.10), at 12 weeks RR was 0.87 (95% CI 0.39
to 1.93; P value 0.7), and at 24 weeks post injection RR was 0.72
(95% CI 0.36 to 1.45; P value 0.4).
Pain on movement was measured as the number of responders (at
least 30% reduction): at two weeks post injection RR was 1.25
(95% CI 0.86 to 1.83; P value 0.2), at four weeks RR was 1.14
(95% CI 0.79 to 1.66; P value 0.5), at eight weeks RR was 1.11
(95% CI 0.74 to 1.66; P value 0.6), at 12 weeks RR was 0.87
(95% CI 0.55 to 1.37; P value 0.5), and at 24 weeks post injection
RR was 0.93 (95% CI 0.53 to 1.63; P value 0.8).
Proportion of OARSI criteria responders (at least 20% decrease in
pain VAS and an absolute change of greater than10 mm and/or
an improvement in function of greater than 20% and an absolute
change of 10 units compared with baseline): at two weeks post
injection RR was 1.45 (95% CI 0.93 to 2.24; P value 0.10), at
four weeks RR was 1.74 (95% CI 1.00 to 3.02; P value 0.05), at
eight weeks RR was 1.66 (95% CI 0.95 to 2.91; P value 0.08), at
12 weeks RR was 1.56 (95% CI 0.84 to 2.90; P value 0.16, and
at 24 weeks RR was 1.98 (95% CI 0.93 to 4.23; P value 0.08).
The RevMan analysis differed from the Smith publication where
a statistically significant difference was found at four weeks post
injection in favour of the steroid group for this outcome (P value
0.004) using a generalized linear model with log link and binary
error distribution to model the RR, and where RR was adjusted
for severity of x-ray grade and baseline score.
Corticosteroid versus joint lavage plus intra-articular placebo:
safety
No statistically significant differences were detected in the total
withdrawals overall (Cortivazol 20% versus joint lavage 19%), RR
was 1.05 (95% CI 0.32 to 3.42; P value 0.9) ; or in the number of
withdrawals due to lack of efficacy (Cortivazol 16% versus joint
lavage 19%), RR was 0.84 (95% CI 0.24 to 2.96; P value 0.8); or
in the number of patients reporting local discomfort (Cortivazol
8% versus joint lavage 19%), RR was 0.42 (95% CI 0.09 to 2.07;
P value 0.3) (Ravaud 1999). In the Smith trial (Smith 2003), the
publication did not report group allocations for the three patients
that required further sutures of arthroscopy portals.
Corticosteroid versus hyaluronan (hyaluronic acid) or hylan
Nine trials compared IA corticosteroid and hyaluronan or hylan:
five with Hyalgan, two with hylan G-F 20 (Synvsic) and two with
Orthovisc.
Corticosteroid versus Hyalgan: efficacy
Five RCTs compared Hyalgan and IA corticosteroid.
Four were comparisons of Hyalgan and methylprednisolone
acetate (Depomedrol (MPA)) (Frizziero 2002; Leardini 1987;
Leardini 1991; Pietrogrande 1991) and one a comparison of Hyal-
gan and triamcinolone hexacetonide (Jones 1995).
There was a statistically significant difference in favour of Hyalgan
for spontaneous pain intensity (0 to 100 mm VAS) at five to 13
weeks post injection (WMD -7.73; 95% CI -12.81 to -2.64; P
value 0.003) (Leardini 1987; Leardini 1991; Pietrogrande 1991),
whenHyalgan was 11 to 41%more effective thanMPA. However,
there were no statistically significant differences between one and
four weeks post injection (WMD -4.90; 95% CI -9.91 to 0.10; P
value 0.05) (Leardini 1987; Leardini 1991; Pietrogrande 1991),
or at 45 to 52 weeks (WMD 2.50; 95% CI -14.98 to 19.98; P
value 0.8) (Leardini 1987).
There was no statistically significant difference at any time point
for pain expressed as the number of joints with moderate or severe
pain under load (Leardini 1987): between one and four weeks post
injection, RR was 1.00 (95% CI 0.47 to 2.14; P value 1), at five
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to 13 weeks post injection, RR was 0.86 (95% CI 0.35 to 2.10;
P value 0.7), at 45 to 52 weeks post injection, RR was 0.82 (95%
CI 0.46 to 1.49; P value 0.5).
There was a statistically significant difference in favour of Hyalgan
for pain expressed as the number of patients with moderate/severe
pain under load (Leardini 1991; Pietrogrande 1991) at five to13
weeks post injection, RR was 0.61 (95% CI 0.44 to 0.84; P value
0.003), when the NNT was 10, but not at one to four weeks post
injection, RR (RE) was 0.90 (95% CI 0.54 to 1.50; P value 0.7).
There were no statistically significant differences in the number
of joints with moderate or severe walking pain detected at the
three time points: one to four weeks post injection, RR was 1.22
(95% CI 0.65 to 2.29; P value 0.5), at five to 13 weeks, RR was
0.80 (95% CI 0.40 to 1.60; P value 0.5), and at 45 to 52 weeks
post injection, RR was 1.04 (95% CI 0.67 to 1.60; P value 0.9)
(Leardini 1987).
There was no statistically significant difference in the number of
patients with moderate or greater night pain at one to four weeks
post injection, RR (RE) was 1.12 (95% CI 0.06 to 21.12; P value
0.9), or at five to 13 weeks, RR was 0.14 (95% CI 0.02 to 1.13;
P value 0.07) (Leardini 1991; Pietrogrande 1991).
There was a statistically significant difference in favour of Hyalgan
for the number of patients with moderate or greater rest pain at
five to 13 weeks post injection, RR was 0.39 (95% CI 0.19 to
0.78; P value 0.008) (Leardini 1991; Pietrogrande 1991), when
the NNT was 20. However, there was no statistically significant
difference at one to four weeks post injection, RR was 0.68 (95%
CI 0.38 to 1.24; P value 0.2).
Statistically significant differences in range of motion (flexion) in
favour of Hyalgan were found at one to four weeks post injection
(WMD 5.93; 95% CI 0.71 to 11.14; P value 0.03), and at five to
13 weeks post injection (WMD 5.41; 95% CI 0.54 to 10.28; P
value 0.03) (Leardini 1987; Pietrogrande 1991) (i.e. Hyalgan was
2% more effective than MPA), but no difference was detected at
45 to 52 weeks post injection (WMD 1.50; 95% CI -12.92 to
15.92; P value 0.8) (Leardini 1987).
The global assessment, expressed by number of patients as ’good’
or ’very good’, showed a statistically significant difference in favour
ofHyalgan at five to 13weeks post injection (WMD1.86; 95%CI
1.26 to 2.75; P value 0.002) (Leardini 1991; Pietrogrande 1991),
when the NNT for patient global assessment is seven. However
there were no significant differences between the groups at one
to four weeks post injection, RR (RE) was 0.98 (95% CI 0.47
to 2.06; P value 1) (Frizziero 2002; Leardini 1991; Pietrogrande
1991), or at 45 to 52 weeks (WMD 1.05; 95% CI 0.81 to 1.36;
P value 0.7) (Frizziero 2002).
TheRCTthat comparedHyalgan and triamcinolone hexacetonide
(Jones 1995) showed no statistically significant differences be-
tween treatments detected by the three pain measures (100 mm
VAS), except for pain at night at 14 to 26 weeks post injection
(WMD -20.70; 95% CI -37.74 to -3.66; P value 0.02), when
Hyalgan was 26%more effective than triamcinolone hexacetonide
in relieving pain. The statistical values supporting these results
were as follows:
Pain on nominated activity: at 14 to 26 weeks post injection
(WMD -10.00; 95% CI -31.83 to 11.83; P value 0.4), and at end
of treatment (WMD -0.20; 95% CI -17.39 to 16.99; P value 1);
Pain at rest: at 14 to 26 weeks post injection (WMD -20.40;
95% CI -43.92 to 3.12; P value 0.09), and at end of treatment
(WMD -0.70; 95%CI -18.17 to 16.77; P value 0.9) (the RevMan
analysis differed from the original analysis by Jones (Jones 1995),
which reported significant differences in favour of Hyalgan in pain
on nominated activity and pain at rest at 14 to 26 weeks post
injection);
Pain at night: at end of treatment (WMD -7.10; 95% CI -24.30
to 10.10; P value 0.4).
Corticosteroid versus Hyalgan: safety
There were no statistically significant differences in any of the
extracted safety outcomes.
For the four trials comparing Hyalgan and MPA, there was no
difference in:
(1) the total number of withdrawals overall: at one to four weeks
post injection, RR was 0.54 (95% CI 0.21 to 1.38; P value 0.2)
(Frizziero 2002), at five to 13 weeks, RR was 3.00 (95% CI 0.13
to 71.74; P value 0.5) (Leardini 1991; Pietrogrande 1991), at 14
to 26 weeks, RR was 1.81 (95% CI 0.67 to 4.91; P value 0.2)
(Frizziero 2002), or at 45 to 52 weeks, RR was 1.67 (95% CI 0.46
to 6.06; P value 0.4) (Leardini 1987);
(2) the number of patients withdrawn due to lack of efficacy: at
five to 13 weeks post injection, RR was 3.00 (95% CI 0.13 to
71.74; P value 0.5 (Pietrogrande 1991);
(3) the number of joints with local reactions: at one to four weeks
post injection, RR was 1.33 (95% CI 0.34 to 5.21; P value 0.7)
(Leardini 1987);
(4) the number of patients with local or systemic reactions: at five
to 13 weeks post injection, RR was 3.00 (95% CI 0.13 to 71.74;
P value 0.5) (Leardini 1991; Pietrogrande 1991);
(5) the number of patients withdrawn due to adverse events after
the first injection in the Frizziero trial (Frizziero 2002), RR was
0.30 (95% CI 0.01 to 7.24; P value 0.5).
There were no statistically significant differences betweenHyalgan
and triamcinolone hexacetonide (Jones 1995) in
(1) the total number of withdrawals overall: at 14 to 26 weeks post
injection RR was 0.80 (95% CI 0.56 to 1.14; P value 0.2), or at
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the end of treatment, RR was 0.73 (95% CI 0.18 to 2.99; P value
0.7);
(2) the number of withdrawals due to lack of efficacy: at 14 to 26
weeks post injection RR was 0.89 (95% CI 0.49 to 1.65; P value
0.7), and at the end of treatment RR was 4.85 (95% CI 0.24 to
97.11; P value 0.3);
(3) the number of withdrawals due to adverse events: at 14 to 26
weeks post injection RR was 0.78 (95% CI 0.23 to 2.62; P value
0.7), and at the end of treatment RR was 0.97 (95% CI 0.06 to
14.82; P value 1).
Corticosteroid versus Hylan G-F 20 (Synvisc)
Two RCTs compared Hylan G-F 20 and IA corticosteroid.
One RCT was a comparison of Hylan G-F 20 and betamethasone
sodium phosphate-betamethasone acetate (Leopold 2003; Redd
2003), the other compared Hylan G-F 20 and triamcinolone hex-
acetonide (Caborn 2004).
Corticosteroid versus Hylan G-F 20 (Synvisc): efficacy
The efficacy outcomemeasure results in the Leopold trial (Leopold
2003) were presented as changes in median scores because the data
were not normally distributed. Therefore, efficacy data for this
RCT are not reported here, though safety data are reported in the
next section.
Statistically significant differences in favour of Hylan G-F 20 com-
pared to triamcinolone hexacetonide were found for the following
outcomes of efficacy in the Caborn trial (Caborn 2004):
(1) WOMAC pain walking on a flat surface (scored 0 to 4): at
five to 13 weeks post injection (WMD -0.40; 95% CI -0.65 to -
0.15; P value 0.002), and at 14 to 26 weeks (WMD -0.40; 95%
CI -0.68 to -0.12; P value 0.005). Hylan G-F 20 was 17% more
effective than triamcinolone hexacetonide;
(2) WOMAC physical function subscale (scored 0 to 68): at five
to 13 weeks post injection (WMD -5.00; 95% CI -8.86 to -1.14;
P value 0.01), and at 14 to 26 weeks post injection (WMD -5.20;
95% CI -9.10 to -1.30; P value 0.009). Hylan G-F 20 was, on
average, 17% more effective than triamcinolone hexacetonide;
(3) WOMAC total score (scored 0 to 96): at five to 13 weeks post
injection (WMD -7.40; 95% CI -12.74 to -2.06; P value 0.007),
and at 14 to 26 weeks post injection (WMD -7.30; 95%CI -12.76
to -1.84; P value 0.009). Hylan G-F 20 was 15% more effective
than triamcinolone hexacetonide;
(4) Patient global assessment (scored 0 to 100 mm VAS): at five to
13 weeks post injection (WMD -13.40; 95% CI -20.03 to -6.77;
P value 0.00007), and at 14 to 26 weeks post injection (WMD
-15.10; 95% CI -22.17 to -8.03; P value 0.00003). Hylan G-
F 20 was approximately 23% more effective than triamcinolone
hexacetonide.
In the Caborn trial (Caborn 2004), there was a statistically signif-
icant difference in the number of responders defined as at least a
one-point improvement in the WOMAC pain walking on a flat
surface in favour of Hylan G-F 20 at five to 13 weeks post injec-
tion, RR was 1.44 (95%CI 1.09 to 1.90; P value 0.01). TheNNT
for the number of responders was five. However, there were no
significant differences at one to four weeks post injection, RR was
1.21 (95% CI 0.96 to 1.53; P value 0.11), or at 14 to 26 weeks,
the RR was 1.44 (95% CI 1.00 to 2.09; P value 0.05). There was
no statistically significant difference in use of analgesics up to 11
weeks post injection, RR was 1.01 (95% CI 0.97 to 1.06; P value
0.6) or from 12 to 26 weeks post injection, RR was 0.84 (95% CI
0.64 to 1.11; P value 0.2).
Corticosteroid versus Hylan G-F 20 (Synvisc): safety
In the Leopold trial (Leopold 2003), there were no statistically
significant differences in safety outcomes: for total withdrawals
overall, RR was 1.56 (95% CI 0.74 to 3.26; P value 0.2); for
withdrawals due to lack of efficacy, RR was 1.50 (95% CI 0.67 to
3.35; P value 0.3); and for withdrawals due to acute local reactions,
RR was 3.31 (95% CI 0.14 to 78.84; P value 0.5).
In the Caborn trial (Caborn 2004), there was a statistically signif-
icant difference in favour of Hylan G-F 20 compared to triamci-
nolone hexacetonide in the number of withdrawals due to lack of
efficacy, RR was 0.03 (95% CI 0.00 to 0.48; P value 0.01). There
were no statistically significant differences in the total number of
withdrawals overall, RR was 0.78 (95% CI 0.52 to 1.17; P value
0.2), or the number of withdrawals due to adverse events, RR was
1.00 (95% CI 0.44 to 2.26; P value 1).
Corticosteroid versus Orthovisc: efficacy
Two trials compared Orthovisc with different IA corticosteroids:
betamethasone (Tekeoglu 1998), and 6-methylprednisolone ac-
etate (6-MPA) (Tascioglu 2003).
At five to 13 weeks post injection in the Orthovisc/betamethasone
trial (Tekeoglu 1998), Orthovisc was significantly better than be-
tamethasone for:
(1) WOMAC function (WMD -9.00; 95% CI -14.15 to -3.85;
P value 0.0006), where Orthovisc was 20% more effective than
betamethasone in improving physical function;
(2) Patient global assessment (i.e. number of patients ’good/very
good’), RR was 1.88 (95% CI 1.04 to 3.39; P value 0.04). The
NNT is three.
However, at one to four weeks post injection there were no statis-
tically significant differences for:
(1) WOMAC function (scored 17 to 85) (WMD 3.00; 95% CI -
2.39 to 8.39; P value 0.3);
(2) the number of patients classified as ’good’ or ’very good’, RR
was 0.83 (95% CI 0.47 to 1.47; P value 0.5); and,
11Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(3) maximum flexion (WMD -4.90; 95% CI -14.69 to 4.89; P
value 0.3). There was also no between-group difference for max-
imum flexion at five to 13 weeks (WMD -7.05; 95% CI -15.48
to 1.38; P value 0.10).
In the Orthovisc/6-methylprednisolone acetate (6-MPA) trial (
Tascioglu 2003) statistically significant differences in favour of
the Orthovisc group were detected in all pain outcomes and the
Lequesne Index at five to 13 weeks post injection:
(1) pain on weight bearing (WMD -15.64; 95% CI -24.51 to -
6.77; P value 0.0006);
(2) pain at rest (WMD -7.70; 95% CI -13.50 to -1.90; P value
0.009);
(3) pain on walking (WMD -18.43; 95% CI -29.19 to -7.67; P
value 0.0008); and
(4) Lequesne Index (WMD -1.40; 95% CI -2.13 to -0.67; P value
0.0002).
Orthovisc was between 25% and 32%more effective than 6-MPA
in relieving pain, and 18% more effective than 6-MPA in improv-
ing function (Lequesne). However, at one to four weeks post injec-
tion, there were no statistically significant differences between the
two groups for any of the pain outcome measures, the Lequesne
Index or flexion outcome measures, or for the latter at five to 13
weeks (WMD 2.36; 95% CI -1.82 to 6.54; P value 0.3).
At 14 to 26weeks post injection, statistically significant differences
in all outcome measures, except pain on rest, were detected in
favour of the Orthovisc group:
(1) pain on weight bearing (WMD -15.40; 95% CI -25.91 to -
4.89; P value 0.004);
(2) pain on walking (WMD -14.90; 95% CI -25.91 to -3.89; P
value 0.008);
(3) Lequesne Index (WMD -1.14; 95% CI -2.16 to -0.12; P value
0.03);
(4) flexion (WMD 5.00; 95% CI 0.19 to 9.81; P value 0.04); and
(5) pain at rest (WMD -2.90; 95% CI -9.47 to 3.67; P value 0.4).
Orthovisc was between 20% and 31%more effective than 6-MPA
in relieving pain, and between 4% and 15% more effective in
improving function.
The RevMan analysis differed from the analysis in the original
trial report (Tascioglu 2003), by detecting previously unreported
statistically significant differences in favour of Orthovisc between
the groups at six months for pain on weight bearing (P value
0.004), pain on walking (P value 0.008), Lequesne Index (P value
0.03), and flexion (P value 0.04).
Corticosteroid versus Orthovisc: safety
There were no adverse local (e.g. post-injection synovitis) or sys-
temic reactions reported in either the Orthovisc or betamethasone
group with all patients completing the Tekeoglue trial (Tekeoglu
1998), and no statistically significant differences in the safety
profile of Orthovisc compared to 6-MPA in the Tascioglu trial
(Tascioglu 2003).
In the Tascioglu trial one patient in each group withdrew due to
increased pain, RR was 1.00 (95% CI 0.07 to 15.26; P value 1),
and a similar number of patients:
(1) were withdrawn overall: Orthovisc 6.7% and 6-MPA 10%,
RR was 0.67 (95% CI 0.12 to 3.71; P value 0.6);
(2) reported musculoskeletal adverse events: Orthovisc 25% and
6-MPA 19%, RR was 1.35 (95% CI 0.49 to 3.74; P value 0.6);
(3) reported adverse skin events: Orthovisc 7% and 6-MPA 4%,
RR was 1.93 (95% CI 0.19 to 20.05; P value 0.6);
(4) reported gastrointestinal adverse events: Orthovisc 11% and
6-MPA 7%, RR was 1.45 (95% CI 0.26 to 7.99; P value 0.7);
(5) reported general adverse events: Orthovisc 14% and 6-MPA
19%, RR was 0.77 (95% CI 0.23 to 2.57; P value 0.7);
(6) reported knee pain after injection: Orthovisc 21% and 6-MPA
19%, RR was 1.16 (95% CI 0.40 to 3.35; P value 0.8).
Corticosteroid versus corticosteroid
Six trials compared different IA corticosteroids against each other
(Bias 2001; Popov 1989; Pyne 2004; Thorpe 1985; Valtonen
1981; Wright 1960).
Corticosteroid versus corticosteroid: pain
Three of the six trials comparing one corticosteroid against another
included pain data that could be used in this review (Bias 2001;
Valtonen 1981; Wright 1960).
In the Valtonen trial (Valtonen 1981), a statistically significant
difference was detected in the number of patients reporting pain
reduction in favour of triamcinolone hexacetonide compared to
betamethasone at one week post injection (76% versus 43%; RR
was 1.78 (95% CI 1.03 to 3.08; P value 0.04)), two weeks (86%
versus 48%; RR was 1.80 (95% CI 1.11 to 2.91; P value 0.02)),
and four weeks (76% versus 38%; RR was 2.00 (95% CI 1.10 to
3.63; P value 0.02)) . The NNTwith triamcinolone hexacetonide
versus betamethasone to achieve an improvement was three.
In the Wright trial (Wright 1960), no statistically significant dif-
ference was detected in the number of knees that improved by two
weeks post injection (hydrocortisone tertiary-butylacetate (66%)
versus hydrocortisone acetate (50%) RR was 1.32 (95% CI 0.89
to 1.95; P value 0.17)).
In the Bias trial (Bias 2001), which compared different doses of
dexamethasone palmitate (4 mg versus 12 mg), there were no
statistically significant differences detected in any pain outcomes:
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(1) Pain during movement (0 to 3) at one week post injection
(WMD -0.20; 95% CI -0.99 to 0.59; P value 0.6), two weeks
(WMD 0.10; 95% CI -0.43 to 0.63; P value 0.7), three weeks
(WMD 0.40; 95% CI -0.34 to 1.14; P value 0.3), or four weeks
(WMD 0.20; 95% CI -0.52 to 0.92; P value 0.6);
(2) Pain at rest (0 to 3) at one week post injection (WMD -0.60;
95% CI -1.37 to 0.17; P value 0.13), two weeks (WMD -0.20;
95% CI -0.53 to 0.13; P value 0.2), three weeks (WMD 0; 95%
CI -0.44 to 0.44; P value 1), or four weeks (WMD -0.20; 95%
CI -0.63 to 0.23; P value 0.4);
(3) Pain on pressure (0 to 3) at one week post injection (WMD
-0.50; 95% CI -1.13 to 0.13; P value 0.12), two weeks (WMD
0; 95% CI -0.40 to 0.40; P value 1), three weeks (WMD -0.10;
95% CI -0.59 to 0.39; P value 0.7), or four weeks (WMD 0.20;
95% CI -0.36 to 0.76; P value 0.5).
Corticosteroid versus corticosteroid: function
Only one of the six trials comparing one corticosteroid against
another included data on function that could be used in this review
(Valtonen 1981). It detected no statistically significant difference
in flexion at four weeks post injection (WMD 0; 95% CI -9.09
to 9.09; P value 1).
Corticosteroid versus corticosteroid: global assessment
Four of the six trials comparing one corticosteroid against another
included global assessment data that could be used in this review
(Popov 1989; Pyne 2004; Thorpe 1985; Valtonen 1981). None
of them showed any statistically significant differences between
treatments for the number of:
(1) patients showing improvement from baseline to three weeks
post injection (triamcinolone hexacetonide 86% versus methyl-
prednisolone acetate 82%; RR was 1.05 (95% CI 0.84 to 1.32; P
value 0.7)), or to eight weeks post injection (triamcinolone hex-
acetonide 52% versus methylprednisolone acetate 64%; RR was
0.80 (95% CI 0.51 to 1.26; P value 0.3)) (Pyne 2004);
(2) patients showing improvement at one week post injection (tri-
amcinolone hexacetonide 90% versus betamethasone 67%; RR
was 1.36 (95% CI 0.97 to 1.89; P value 0.07)) (Valtonen 1981);
(3) patients who had improved at one week post injection (triam-
cinolone acetonide 100% versus hydrocortisone acetate 92%; RR
was 1.09 (95% CI 0.92 to 1.29; P value 0.3)) (Popov 1989);
(4) knees that were assessed as ’excellent’ or ’good’ by the physi-
cian at 20 weeks post injection (triamcinolone acetate 63% versus
methylprednisolone 59%; RR was 1.07 (95% CI 0.73 to 1.56; P
value 0.7)) (Thorpe 1985).
Corticosteroid versus corticosteroid: other outcome measures
In the Bias trial (Bias 2001), which compared different doses of
dexamethasone palmitate (4 mg versus 12 mg), no statistically sig-
nificant differences were detected in the activity index to assess
the degree of inflammation (scored 0 to 10: based on pain, tem-
perature, effusion, swelling) at one week post injection (WMD -
0.60; 95% CI -1.69 to 0.49; P value 0.3), two weeks (WMD -
0.40; 95% CI -1.48 to 0.68; P value 0.5), three weeks (WMD -
0.10; 95% CI -1.28 to 1.08; P value 0.9), or four weeks (WMD
-0.40; 95% CI -1.77 to 0.97; P value 0.6).
Corticosteroid versus corticosteroid: safety
No statistically significant differences were detected in the Valto-
nen trial (Valtonen 1981), for the number of patients reporting
local pain after injection (triamcinolone hexacetonide 19% versus
betamethasone 5%; RR was 4.00 (95% CI 0.49 to 32.87; P value
0.2)); or in the Wright trial (Wright 1960) for the number of pa-
tients reporting local pain after injection (hydrocortisone acetate
0% versus hydrocortisone tertiary-butylacetate 5%; RR was 5.00
(95% CI 0.25 to 100.81; P value 0.3)).
No adverse events were reported for any patient in the Bias trial
(Bias 2001) comparing 4mg and 12mg dexamethasone palmitate.
D I S C U S S I O N
The comparisons of IA corticosteroid and IA placebo provide ev-
idence of benefit for pain and patient global assessment at one
week post injection (NNT of three to four for both, based on n
= 185 for pain on 100 mm VAS and n = 158 for patient global
assessment). The analyses do not provide evidence for effects on
function, possibly because the data are sparse. There was evidence
at two to three weeks post injection that corticosteroid was more
effective than placebo in pain reduction, but a lack of evidence for
benefit in functional improvement. From four to 24 weeks post
injection, there was no compelling evidence of benefit, although
some mid and late stage benefit in favour of corticosteroids was
noted. Therefore, it appears that the beneficial effects of IA cor-
ticosteroids are rapid in onset, but may be relatively short lived
(approximately one to three weeks). In contrast, the beneficial ef-
fects of the HA products (Hyalgan, Hylan G-F 20 and Orthovisc)
are of similar or slower onset, but are more durable, with clinical
benefit being detected at five to 13 weeks post injection.
Compared to other pharmacological treatments for OA, e.g.
NSAIDs, very few randomised, controlled trials have been pub-
lished comparing different IA corticosteroids. In the compar-
isons between IA corticosteroid preparations, only one study de-
tected a statistically significant difference in reduction of pain,
and favoured triamcinolone hexacetonide over betamethasone.No
other differences were detected in any of the efficacy or safety out-
come measures. Given the relative paucity of head-to-head studies
of IA corticosteroid preparations, the results of our analyses do not
permit broad generalisation.
In the comparisons between IA corticosteroid (Cortivazol) and
joint lavage, no differences were detected in any of the efficacy or
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safety outcome measures.
The explanation for the variability in response to IA corticosteroids
is contentious. Jones suggested that it could be partly attributable
to inaccurate injection (Jones 1993). He showed that the place-
ment of IA injections is often inaccurate, which may contribute
to the incidence of local tissue damage (atrophy of soft tissue and
fat). Gaffney (Gaffney 1995) suggested that the accuracy of in-
jection could relate to the association between pain relief and the
successful aspiration of synovial fluid.
A mail survey of rheumatologists in New South Wales showed
wide variation in aseptic techniques and number of weekly injec-
tions (Lawford 1994). This survey also reported a wide variety of
soft tissue complications, e.g. tendon rupture, soft tissue infection,
neuropraxia (a condition in which after injury a nerve remains in
place but does not transmit electrical impulses), and subcutaneous
skin atrophy (wasting away of tissue). Bliddal proposed mini air-
arthrography as a means of quality assurance in studies involving
IA injections (Bliddal 1999). The use of ultrasound to guide IA
injections has also been investigated (Brown 2001; Fredberg 2001;
Qvistgaard 2001). In a double-blind randomised study, Sambrook
(Sambrook 1989) compared a peripatellar (around the kneecap)
route of injection to a more standard IA route using methylpred-
nisolone in 38 patients with knee OA. They concluded that peri-
patellar injection was at least as useful as the standard IA injection
technique. Recognizing the importance of joint aspiration and in-
jection, Sack published a how-to-guide (Sack 1999) and more re-
cently Schumacher a review on aspiration and injection therapies
for joints (Schumacher 2003).
Clinical improvementmay be due to treatment effect, reflect spon-
taneous improvement (Ravaud 1999), or natural remission during
the course of the trial (Popov 1989). Jones (Jones 1996) found no
predictors of response; and responsewas not confined to those with
clinical evidence of inflammation. It has been suggested that there
are subgroups of people who do, and do not, respond. Dieppe
(Dieppe 1980a; Dieppe 1980b) queried whether different types
of OA respond differently to IA steroid therapy. He found no ob-
vious correlations with clinical, radiological or synovial fluid find-
ings except for positive results occurring in all those with chondro-
calcinosis (calcium pyrophosphate crystals present in joint carti-
lage). Gaffney (Gaffney 1995) questioned whether the clinical re-
sponse was related more to injection accuracy than the response of
a subgroup. His subgroup analysis of triamcinolone hexacetonide-
treated patients revealed that improvement for pain (on VAS) was
greater among patients with clinical evidence of joint effusion and
those who had synovial fluid successfully aspirated at time of in-
jection. In contrast, Jones (Jones 1996) found that synovial fluid
aspiration did not predict clinical response.
This review cannot evaluate any dose-response relationship with
the different corticosteroid preparations. All the included trials
used a fixed dose in their design. However, a number of ob-
servations are worth noting. Miller (Miller 1958) could not at-
tribute any effect produced to the volume of fluid injected. Popov
(Popov 1989) recommended hydrocortisone acetate as the drug
of choice as his studies showed equal efficacy of low dose hydro-
cortisone acetate (50 mg) with more than average triamcinolone
acetonide doses. Thorpe’s trial (Thorpe 1985) results showed that
smaller doses of triamcinolone acetonide may be more effective
than methylprednisolone acetate, with 10 mg of triamcinolone
acetonide being equivalent to 40 mg methylprednisolone acetate.
Valtonen (Valtonen 1981) reported that the duration of effect of
triamcinolone was substantially longer than that of betametha-
sone. No statistically significant difference was reported between
hydrocortisone acetate and hydrocortisone tertiary-butylacetate
(Wright 1960).
A mail survey of members of the American College of Rheumatol-
ogy (ACR) indicated that the corticosteroids favoured by the re-
spondents depended upon place of training: methylprednisolone
acetate was preferred by those trained in the eastern United States,
triamcinolone hexacetonide by those trained in the Midwest and
Southwest, and triamcinolone acetonide by those trained in the
West (Centeno 1994). Only triamcinolone hexacetonide was cho-
sen primarily because of efficacy. Respondents used 1 ml of steroid
combined with local anaesthetic. Twenty-nine percent did not re-
strict weight bearing while 8% recommended limited weight bear-
ing for one week or more post injection.
The results of a British mail survey of consultant rheumatologists
showed wide divergence regarding personal and patient prepara-
tion before IA injections (Haslock 1995). Approximately 25%
used no local anaesthetic. Most advised rest or reduced use of
weight-bearing joints for 24 to 48 hours post injection. Con-
cern has been raised that repeated IA corticosteroid injections
might cause progressive cartilage damage. Lane (Lane 1997) rec-
ommended that IA corticosteroid injections should not be given
in a single joint at more than three monthly intervals. Similarly,
Ratiner(Ratiner 2001) recommended that there should be nomore
than two to three injections per joint per year in routine cases.
It has been suggested that the short term benefits of reduced pain
and inflammation have to be weighed against possible adverse ef-
fects concerning the “articular cartilage, the synovium and the host
immune response” (Gosal 1999). Albeit uncommon, complica-
tions of IA corticosteroids include the following: post injection
flare (reddening of the skin), crystal-induced synovitis (inflamma-
tion of joint membranes), tissue atrophy (wasting of tissue), fat
necrosis, calcification (deposition of calcium salts in tissue), sepsis
(tissue destruction by bacteria or their toxins), steroid arthropa-
thy (acceleration of cartilage damage), vascular necrosis (death of
blood vessels), and haematoma (swelling caused by accumulation
of blood) (Ayral 2001; Lawford 1994; McColl 2000; Noerdlinger
2001; Ratiner 2001; Rozental 2000; Seror 1999; Wada 1993).
Rarely, absorption of IA corticosteroid from the joint through the
body may result in fluid retention, hyperglycaemia (toomuch glu-
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cose in the blood) and hypertension (Ratiner 2001). The rare oc-
currence of sepsis after IA corticosteroids in the osteoarthritic knee
following arthroscopy deserves some consideration (Gosal 1999;
Gosal 2000; Peckett 2000). From the RCTs reviewed, no serious
adverse events were reported. The safety of repeat IA injections is
not adequately addressed bymost of the RCTs reviewed, which did
not investigate them. Long-term safety (greater than six months) is
difficult to address from the RCTs reviewed, as seven of themwere
of eight weeks’, or less, duration. As described in the ’Description
of studies’ section above, very few adverse events were reported.
Risks can be minimised by accuracy of IA injection (Jones 1993)
and adherence to an appropriate sterile technique (McColl 2000).
This review may have missed negative trials that might have been
conducted, but may not have been submitted, or accepted, for
publication. Manufacturers were contacted for unpublished data,
but none have been received. We have observed that in some anal-
yses, RevMan 4.1.1 output differs from the original publication
(Table 19). The discrepancies are probably due to the use of sec-
ondary data taken from trial papers rather than directly from par-
ticipants and the statistical methods available within the software
programme. Readers are advised to consider these disparities when
making product-based evaluations.
The comparative study of Hyalgan against IA triamcinolone hex-
acetonide (Jones 1995) suggests that there is no difference in ben-
efit between Hyalgan and triamcinolone hexacetonide, except in
pain at night between 14 to 26 weeks. Analyses of safety data
supported the safety of Hyalgan, with no statistically significant
differences from IA triamcinolone hexacetonide being detected
in safety variables. Comparative studies of IA methylprednisolone
against Hyalgan (Frizziero 2002; Leardini 1987; Leardini 1991;
Pietrogrande 1991) suggest that Hyalgan is more effective than
methylprednisolone at five to 13 weeks post-injection for spon-
taneous pain intensity, number of patients with moderate/severe
pain under load, number of patients with ’moderate’ or ’greater’
rest pain, flexion (at one to four weeks too), patient global assess-
ment. No statistically significant differences were detected at 14 to
26 weeks or 45 to 52 weeks post-injection. These differences are
probably due to the quick onset, but often relatively short dura-
tion, of the response to IA corticosteroid treatment. Overall, these
analyses suggest that Hyalgan, with its longer duration of action,
is comparable, or more effective than methylprednisolone, even
though the latter has a faster onset of action. Analyses of safety
data also supported the safety of Hyalgan, with no statistically sig-
nificant differences from IA methylprednisolone being detected
in safety variables. Collectively these data support the efficacy and
safety of Hyalgan, and show some five to 13 week post-injection
advantages in favour of Hyalgan over methylprednisolone.
Comparative studies of IA corticosteroid against Hylan G-F 20
suggest that Hylan G-F 20 is superior to triamcinolone hexace-
tonide at five to13 weeks (Caborn 2004), and 14 to 26 weeks post-
injection on WOMAC pain walking on a flat surface, WOMAC
function and total WOMAC score, but not at one to four weeks.
This difference is probably due to the quick onset, but often rel-
atively short duration, of the response to IA corticosteroid treat-
ment. Overall, these analyses suggest that Hylan G-F 20, with
its longer duration of action, is as beneficial as IA corticosteroid,
notwithstanding the latter’s faster onset of action. Analyses of sa-
fety data also supported the safety of Hylan G-F 20, with no sta-
tistically significant differences from IA corticosteroid being de-
tected in the majority of safety variables.
Comparative studies of IA corticosteroid against Orthovisc sug-
gest that Orthovisc is superior to 6-MPA (Tascioglu 2003) at five
to 13 weeks, and 14 to 26 weeks post-injection, and superior to
betamethasone (Tekeoglu 1998) at five to 13 weeks post-injection.
No statistically significant differences were detected at one to four
weeks against either corticosteroid. This time-dependent differ-
ence is probably due to the quick onset, but often relatively short
duration, of the response to IA corticosteroid treatment. Overall,
these analyses suggest that Orthovisc, with its longer duration of
action, is as beneficial as IA corticosteroids at one to four weeks,
and superior at five to 13 weeks and 14 to 26 weeks, notwithstand-
ing the latter’s faster onset of action. Analyses of safety data also
support the safety of Orthovisc, with no statistically significant
differences of either IA corticosteroid preparation detected in the
safety profile.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the comparisons between intra-articular (IA) corticosteroid and
IA placebo, some evidence for efficacy was detected for pain and
patient global assessment, at one week post injection, with evi-
dence also for continuing efficacy at two and three weeks post-
injection. Thereafter, there is diminishing evidence for efficacy,
partly due to an absence of data, and partly to an inability to detect
statistically significant differences in longer term follow-up. There
seem to be beneficial effects on pain and patient global assess-
ment, but little or no effect (versus placebo) on function. There
is justification, therefore, for the use of IA corticosteroid therapy
in selected patients with osteoarthritis of the knee (OA knee). In
contrast the effect of Hyaluronic acid or hylan (HA) products on
OA knee, while slower in onset, appear to be more durable than
IA corticosteroids. Therefore, clinicians have therapeutic options
for IA therapy, and need to choose between IA corticosteroids and
HA products. In cases where there are obvious signs of inflamma-
tion, a corticosteroid preparation may offer opportunity for relief
of inflammation and short term pain relief, while, in other cases,
HA products (Hylan G-F 20, Hyalgan, Orthovisc) may offer a
longer more durable response with improvement in pain, function
and patient global assessment than IA corticosteroids provide.
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Our analyses do not permit us to differentiate between corticos-
teroid products. Triamcinolone hexacetonide was superior to be-
tamethasone for the number of patients reporting pain reduction
up to four weeks post injection, but no other clinically or statis-
tically important differences were detected in comparisons of dif-
ferent corticosteroid products.
Overall the analyses suggest that several IA corticosteroid prepara-
tions are efficacious in short term symptomatic treatment of OA
knee. Their onset of action is fast, with effects on pain detectable
at one week post-injection, and lasting for two to three weeks.
Some patients experience more dramatic and prolonged symptom
relief than others. The basis for this variability in response requires
further study.
Implications for research
The usefulness of trials of IA corticosteroid in patients with OA
of the knee has been restricted through the lack of standardisation
of outcome assessments, variable assessment times, and durations.
Standardisation of outcome measurement procedures would facil-
itate inter-trial comparisons, while trials of longer duration (e.g.
greater than one month), examining different patient subgroups,
and following robust guidelines for trial conduct and design would
be valuable. Clinical predictors of response should be further in-
vestigated, in particular those associated with inflammation and
structural damage.
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